Browse > Article

Gefitinib-induced Acute Fatal Respiratory Failure in a Woman who Never Smoked and had Adenocarinoma of the Lung with EGFR Mutation  

Kim, Sang-Gu (Department of Internal Medicine, College of Medicine, Inha University)
Ryu, Jeong-Seon (Department of Internal Medicine, College of Medicine, Inha University)
Han, Jee-Young (Department of Internal Medicine, College of Medicine, Inha University)
Kim, Hyun-Jung (Department of Internal Medicine, College of Medicine, Inha University)
Cho, Jae-Hwa (Department of Internal Medicine, College of Medicine, Inha University)
Kwak, Seung-Min (Department of Internal Medicine, College of Medicine, Inha University)
Lee, Hong-Lyeol (Department of Internal Medicine, College of Medicine, Inha University)
Publication Information
Tuberculosis and Respiratory Diseases / v.64, no.1, 2008 , pp. 44-47 More about this Journal
Keywords
Acute respiratory failure; Gefitinib; Lung cancer;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56   DOI   ScienceOn
2 Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin- induced lung fibrosis in mice. Am J Respir Crit Care Med 2006;174:550-6   DOI   ScienceOn
3 Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 2003;14:665-8   DOI   ScienceOn
4 Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-4   DOI   ScienceOn
5 Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003;40:339-42   DOI   ScienceOn
6 Seto T, Seki N, Uematsu K, Tanigaki T, Shioya S, Koboyashi T, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology 2006;11:113-6   DOI   ScienceOn
7 Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9   DOI   ScienceOn
8 Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8   DOI
9 Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104   DOI   ScienceOn
10 Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2006;52:99-103   DOI   ScienceOn
11 Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-9
12 Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003;22:179-81   DOI
13 Sumpter K, Harper-Wynne C, O'Brien M, Congleton J. Severe acute interstitial pnuemonia and gefitinib. Lung Cancer 2004;43:367-8   DOI   ScienceOn
14 Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004;9:406-9   DOI   ScienceOn
15 Inomata S, Takahashi H, Nagata M, Yamada G, Shiratori M, Tanaka H, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004;15:461-7   DOI   ScienceOn